Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Banyu Pharmaceutical Co. Ltd

Terence G Hamill

H Donald Burns

Raymond E Gibson

Ping Liu

Linus S Lin

Craig William Lindsley

William K Hagmann

Mark T Goulet

Takehiro Fukami

Robert J DeVita

James Patrick Jewell

Wai-Si Eng

Marc D Chioda

Andrey V Peresypkin

Alex Minhua Chen

Wenping Li

Robert J Devita

The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

Imidazole derivatives useful as modulators of FAAH and as FAAH imaging agents

The present invention is directed to radiolabeled glycine transporter inhibitors which are useful for the labeling and diagnostic imaging of glycine transporters in mammals.

Radiolabeled glycine transporter inhibitors

The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.

Radiolabeled cannabinoid-1 receptor modulators

The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.

Radiolabeled neurokinin-1 receptor antagonists

The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.

Radiolabeled neuropeptide Y Y5 receptor antagonists

The present invention is directed toward radiolabeled farnesyl-protein transferase inhibitor compounds which are useful to label FPTase in assays, whether cell-based, tissue-based or in whole animal. The tracers can also be used in competitive binding assays to obtain information on the interaction of unlabeled FTIs with FPTase.

Radiolabeled farnesyl-protein transferase inhibitors

F-18 radiolabeled neurokinin-1 receptor antagonists

Growing community of inventors

Lansdale, PA, United States of America

Terence G Hamill